Core Viewpoint - Anping announced the approval of a plan to utilize idle raised funds for cash management, with a limit of up to RMB 140 million, ensuring that it does not affect the normal investment plans of the raised funds [1] Group 1 - The company will use the idle funds for purchasing high-security, high-liquidity investment products, including but not limited to structured deposits, time deposits, notice deposits, large certificates of deposit, and agreed deposits [1] - The cash management products cannot be used for pledging or for investment purposes in securities [1] - The funds within the approved limit can be used in a rolling manner, and the usage period is valid for 12 months from the date of board approval [1]

Core Insights - Anbiping reported a significant decline in revenue and net profit for the first half of 2025, indicating financial challenges faced by the company [1] Financial Performance - The company achieved operating revenue of 159,397,066.02 yuan, representing a year-on-year decrease of 30.11% [1] - The net profit attributable to shareholders was -12,498,511.13 yuan, reflecting a year-on-year decline of 176.38% [1]

Group 1 - The core point of the article is that Anbiping announced the approval of multiple proposals during the ninth meeting of its fourth supervisory board [2] Group 2 - The announcement was made on the evening of August 21 [2] - The proposals included the company's summary and other related matters [2]

人民财讯8月21日电，安必平(688393)8月21日晚间披露2025年半年度报告，上半年实现营业收入1.59亿 元，同比下降30.11%；归母净利润-1249.85万元，同比由盈转亏；基本每股收益-0.13元。 ...

Core Points - The company Anbiping (688393.SH) plans to use up to RMB 140 million of temporarily idle raised funds for cash management, ensuring that it does not affect the normal progress of fundraising investment plans [1] Group 1 - The company will utilize the funds within the specified limit for rolling use during the investment period [1]

Core Viewpoint - The company has completed the fundraising project for the application development of a tumor companion diagnostic technology platform and has decided to conclude the project, utilizing the raised funds effectively [1] Group 1 - The company has fully utilized the raised funds for the project, achieving the main research and development goals [1] - The remaining raised funds amounting to 14,800 yuan will be permanently added to the company's working capital [1]

Core Viewpoint - Anbiping (688393.SH) plans to use up to RMB 140 million of temporarily idle raised funds for cash management without affecting the normal operation of its fundraising investment plan [1] Group 1 - The company will utilize the idle funds within a specified limit for cash management purposes [1] - The funds can be used in a rolling manner during the investment period [1]

Meeting Overview - The fourth session of the Supervisory Board of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. was held on August 21, 2025, combining in-person and remote participation [1] - The meeting was convened by Chairwoman Jin Xinyu, with all three supervisors participating in the voting [1] Resolutions Passed - The Supervisory Board approved the "2025 Half-Year Report" and its summary, confirming that the report accurately reflects the company's financial status and operational results for the reporting period [1][2] - The board also approved the "Special Report on the Storage and Actual Use of Raised Funds for the First Half of 2025," which disclosed the management of raised funds without any misappropriation or harm to shareholder interests [2] - Approval was granted for the use of up to 140 million yuan of temporarily idle raised funds for cash management, ensuring compliance with relevant regulations and not affecting the normal implementation of investment projects [3] - The board agreed to temporarily adjust the use of idle spaces from fundraising investment projects for external leasing, which aligns with the company's operational stability [4]

Meeting Information - The shareholder meeting is scheduled for September 9, 2025 [1] - The meeting will be held at the company's conference room located at No. 2, Kexin Street, Huangpu District, Guangzhou [4] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [1][2] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's network voting system, with specific time slots for voting on the meeting day [1][3] - The voting time for the trading system is from 9:15-9:25, 9:30-11:30, and 13:00-15:00, while the internet voting platform is available from 9:15 to 15:00 [1][3] Agenda Items - The meeting will review a proposal to temporarily adjust the use of idle funds from fundraising projects [2] - The proposal has already been approved by the fourth board of directors and the supervisory board [2] Registration Details - Shareholders must register by presenting their ID and shareholder account card at the company's securities department by September 8, 2025 [5] - Registration can also be done via mail, which must arrive by September 8, 2025 [5] Attendance - Attendees include A-share shareholders, company directors, supervisors, senior management, and appointed lawyers [7] - The company will not provide gifts, and attendees are responsible for their own travel and accommodation expenses [6]

广州安必平医药科技股份有限公司 关于 2025 年度"提质增效重回报"专项行动方案的 半年度评估报告 为积极践行"以投资者为本"的上市公司发展理念，响应上海证券交易所《关 于开展沪市公司"提质增效重回报"专项行动的倡议》，广州安必平医药科技股 份有限公司（以下简称"公司"）于 2025 年 4 月发布了《2025 年度"提质增效 重回报"行动方案》。公司根据行动方案内容，积极开展和落实各项工作，现将 一、 聚焦病理诊断领域，推动病理"四化" 公司业务主要集中在医院病理科，经过多年发展已经覆盖了诊断试剂及原料、 制片读片自动化一体机、辅助诊断人工智能软件等全产业链条。搭建完成液基细 胞学（LBP） 、聚合酶链式反应（PCR）、免疫组织化学（IHC）和荧光原位杂交（FISH） 四大病理诊断方法学，是国内方法学最全的病理诊断公司，并在各产品线进行"试 剂+自动化设备+数字化产品+人工智能辅助诊断系统"的病理诊断数智化升级。 报告期内，公司新获批 12 项诊断相关注册/备案证，截至报告期末，拥有国内超 现归属于母公司所有者的净利润-1,249.85 万元，同比下降 176.38%。受内外部 因素影响，上半年公司经营层 ...